The MMS are clearly in control here. to bring it down maybe in advance of the company or any of their invested companies making a stausannpuncement on progress and future milestones.
I would thought it would hold up better but it is thinly traded
They have three drugs with orphan designations one due in August and don't know on the other two.
The PPS and the people in the know braced them selves for the drop to 35 percent ownership in Biohaven after the $80 M funding. Investors perceived this as being a negative impact on the stock but we really gained. value
49percent of market value before funding $130 M equals $63M
35 percent of $130 plus $80 M cash equals $210 M equals $73 M